Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Pathology in Prenatal Test Alliance

NEW YORK (GenomeWeb News) – CombiMatrix today said that Pathology, Inc. will market and distribute its chromosomal microarray tests for "products of conception" testing in designated areas in the US.

Products of conception testing enables physicians to better determine if there is a genetic cause behind a miscarriage or multiple events, said Irvine, Calif.-based CombiMatrix.

Under terms of the agreement, Pathology will market and distribute the tests in California and Nevada, as well as the Chicago and St. Louis metropolitan areas. The firms will participate in sales force training and market development activities, and Torrance, Calif.-based Pathology will need to generate a minimum amount of tests each quarter to maintain its exclusive rights in the designated markets.

Further terms of the agreement were not disclosed.

CombiMatrix President and CEO Judd Jessup said that the agreement with Pathology will enable the firm to expand its geographical reach and access to the women's health market.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.